European Journal of Clinical Pharmacology

, Volume 33, Issue 4, pp 349–354 | Cite as

Haemodynamic effects of combined oral nifedipine and sublingual nitroglycerin in patients with chronic stable angina

  • K. M. Boje
  • H. L. Fung
  • K. Yoshitomi
  • J. O. Parker


We examined the pharmacokinetics of nifedipine after acute and sustained oral therapy and the potential haemodynamic interaction between nifedipine and sublingual nitroglycerin in nine patients with chronic stable angina.

Nifedipine pharmacokinetics after a single oral dose and sustained dosing (three times daily for five days) were not significantly different. Single dose nifedipine produced a statistically significant decrease in standing and supine systolic and diastolic blood pressures when compared to placebo. A significant decrease in the supine systolic pressure was observed after sustained nifedipine therapy. Except for this change, other hypotensive effects of nifedipine after sustained therapy were not different to those of placebo, in spite of persistent plasma nifedipine concentrations after repeated dosing.

There were no observable correlations between nifedipine haemodynamics and pharmacokinetics in these patients, nor were there any significant haemodynamic interactions between sublingual nitroglycerin with either acute or sustained nifedipine treatment.

The transient haemodynamic effects of sublingual nitroglycerin were not potentiated by either acute or sustained nifedipine therapy.

Key words

nifedipine nitroglycerin nifedipine haemodynamics nifedipine-nitroglycerin therapy angina pectoris 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Boje KM, Dolce JA, Fung H-L (1984) Oral ethanol ingestion altered nifedipine pharmacokinetics in the rat: A preliminary study. Res Commun Chem Pathol Pharmacol 46: 219–226Google Scholar
  2. 2.
    Yap PSK, McNiff EF, Fung H-L (1978) Improved GLC determination of plasma nitroglycerin concentrations. J Pharm Sci 64: 582–584Google Scholar
  3. 3.
    Metzler CM, Elfring GL, McEwen AJ (1974) A package of computer programs for pharmacokinetic modelling. Biometrics 30: 562Google Scholar
  4. 4.
    Rocci ML, Jusko WJ (1983) LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 16: 203–216Google Scholar
  5. 5.
    Guenther WC (1964) Analysis of variance. Prentice-Hall, New JerseyGoogle Scholar
  6. 6.
    Riggs DS, Guarnieri JA, Addelman S (1978) Fitting straight lines when both variables are subject to error. Life Sci 22: 1305–1360Google Scholar
  7. 7.
    Armstrong PW, Armstrong JA, Marks GS (1979) Plasma levels following sublingual nitroglycerin. Circulation 59: 585–588Google Scholar
  8. 8.
    Feldman RL, Hill JA, Conti JB, Pepine CJ (1983) Analysis of coronary responses to nifedipine alone and in combination with intracoronary nitroglycerin in patients with coronary artery disease. Am Heart J 105: 651–658Google Scholar
  9. 9.
    Cohen DJ, Foley RW, Ryan JM (1983) Introaperative coronary artery spasm successfully treated with nitroglycerin and nifedipine. Ann Thorac Surg 36: 97–100Google Scholar
  10. 10.
    Kubo SH, Fox SC, Prida XE, Coda RJ (1985) Combined hemodynamic effects of nifedipine and nitroglycerin in congestive heart failure. Am Heart J 110: 1032–1034Google Scholar
  11. 11.
    Foster TS, Hamann SR, Richards VR, Bryant PJ, Graves DA, McAllister RG (1983) Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol 23: 161–170Google Scholar
  12. 12.
    Kleinbloesem CH, van Brummelen P, van de Linde JA, Boogd PJ, Breimer DD (1984) Nifedipine: Kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 35: 742–749Google Scholar
  13. 13.
    Kanda K, Flaim SF (1984) Effects of nifedipine on total cardiac output distribution in conscious rat. J Pharmacol Exp Ther 228: 711–718Google Scholar
  14. 14.
    Fung H-L, Blei A, Chong S (1986) Cardiac output is an apparent determinant of nitroglycerin pharmacokinetics in rats. J Pharmacol Exp Ther 239: 701–705Google Scholar
  15. 15.
    Feely J (1984) Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects. Br J Clin Pharmacol 17: 83–85Google Scholar
  16. 16.
    Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390Google Scholar
  17. 17.
    Pang KS, Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5: 625–653Google Scholar
  18. 18.
    Blei AT, Gottstein J, Fung H-L (1984) The role of the liver in the disposition of intravenous nitroglycerin in the rat. Biochem Pharmacol 33: 2681–2688Google Scholar
  19. 19.
    Husted SE, Kraemmer Nielsen H, Christensen CK, Lederballe Pedersen O (1982) Long-term therapy of arterial hypertension with nifedipine given alone or in combination with a beta-adrenoceptor blocking agent. Eur J Clin Pharmacol 22: 101–103Google Scholar
  20. 20.
    Kleinbloesem CH, van Brummelen P, Faber H, Breimer DD (1987) Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients. J Cardiovasc Pharmacol 9: 202–208Google Scholar
  21. 21.
    Kleinbloesem CH, van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer DD (1987) Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 41: 26–30Google Scholar
  22. 22.
    Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New YorkGoogle Scholar
  23. 23.
    Traube M, Hongo M, McAllister RG, McCallum RW (1985) Correlation of plasma levels of nifedipine and cardiovascular effects after sublingual dosing in normal subjects. J Clin Pharmacol 25: 125–129Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • K. M. Boje
    • 1
  • H. L. Fung
    • 1
  • K. Yoshitomi
    • 2
  • J. O. Parker
    • 2
  1. 1.Department of PharmaceuticsState University of New York at BuffaloAmherstUSA
  2. 2.Division of Cardiology, Department of MedicineQueen's UniversityKingstonCanada

Personalised recommendations